Welcome to our dedicated page for Fate Therapeutic SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fate Therapeutics files SEC reports that document its clinical-stage biopharmaceutical business and its iPSC-derived cellular immunotherapy pipeline for cancer and autoimmune diseases. Current reports furnish operating results and business updates, including disclosures on FT819, FT836 and other off-the-shelf CAR T-cell programs, FDA-related development matters, clinical presentations, and costs associated with restructuring actions.
Proxy and current-report filings cover board and compensation governance, equity-plan matters, Regulation FD disclosures, and capital-structure details for FATE common stock listed on the Nasdaq Global Market. The filings also record material events affecting operations and public-company reporting obligations.
FATE Therapeutics director William H. Rastetter exercised stock options to acquire 25,000 shares of Common Stock at $1.69 per share. Following the exercise, he holds 36,331 Common shares directly. In addition, 459,272 shares are held indirectly by The Investment 2002 Trust and 146,821 shares are held indirectly by The Rastetter Family Trust, where he serves in trustee roles.
Fate Therapeutics, Inc. is asking stockholders to vote at its June 12, 2026 annual meeting on four key items: electing three Class I directors, ratifying Ernst & Young LLP as auditor, approving a non-binding Say-on-Pay proposal, and expanding its equity plan.
The board seeks approval to amend and restate the 2022 Stock Option and Incentive Plan to add 7,000,000 shares, increasing the reserve from 24,500,000 to 31,500,000 shares, an amount described as 6.0% of shares outstanding as of March 31, 2026. The proxy also details board independence, committee structure, director compensation (including higher cash retainers and larger option grants), voting mechanics such as broker non-votes, and procedures and deadlines for future stockholder proposals and director nominations.
Fate Therapeutics shareholder Redmile Group filed an amended Form 4 to update the terms of cash-settled swap positions tied to Fate common stock. The amendment corrects the reference price associated with swap agreements that were internally reorganized.
The swaps, representing an economic interest in 266,280 notional shares of common stock per reported leg, were novated from RedCo II Master Fund to two wholly owned subsidiaries on a pro‑rata basis, for no consideration and with no change in other terms. Footnotes state this internal reorganization caused no change in the aggregate beneficial ownership or economic exposure of Redmile or its principal Jeremy Green.
The swaps are cash‑settled and give Redmile-managed clients economic exposure to Fate’s share price movements without voting, investment, or dispositive control over Fate shares. Cash flows at settlement depend on the difference between the corrected reference price of $5.84 per notional share and the market price at close‑out.
Fate Therapeutics insider RedCo II Master Fund, L.P., an investment vehicle managed by Redmile Group, completed an internal reorganization of its holdings. RedCo II distributed its Fate Therapeutics common stock, Class A convertible preferred stock, pre-funded warrants, and cash-settled swaps pro rata and in kind to two wholly owned subsidiaries, for no consideration.
Following this, RedCo II no longer has voting or dispositive power over these securities, is no longer a more-than-10% beneficial owner, and will be dissolved. The filing states the reorganization caused no change in the aggregate beneficial ownership of Redmile Group or its principal, Jeremy Green.
Fate Therapeutics’ large shareholder Redmile Group has updated its ownership report following an internal reorganization of its investment vehicles. RedCo II Master Fund, L.P. transferred all its Fate securities to two wholly owned SPVs, including RedCo II Offshore SPV LLC, for no consideration.
After the reorganization, RedCo II Master Fund no longer beneficially owns more than 5% of Fate’s common stock and will be dissolved, while RedCo II Offshore SPV became a more‑than‑5% holder. Redmile Group and Jeremy C. Green may be deemed to beneficially own 18,229,078 shares of common stock, or 14.9% of the class, including shares issuable from options, Class A Preferred Stock and Pre-Funded Warrants, with overall aggregate ownership unchanged.
Fate Therapeutics Inc ownership update: The Vanguard Group filed Amendment No. 6 to its Schedule 13G/A reporting that it beneficially owns 0 shares of Common Stock, representing 0% of the class as reported. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries report ownership separately. The amendment is signed on 03/26/2026.
Fate Therapeutics presents an in-depth annual overview of its strategy to develop off-the-shelf, iPSC-derived cellular immunotherapies for autoimmune diseases and cancer. The company engineers clonal iPSC master lines to mass-produce uniform T-cell and NK-cell therapies designed for on-demand, broad patient access.
The pipeline centers on FT819, a CD19-targeted CAR T-cell for systemic lupus erythematosus and other B cell–mediated autoimmune diseases, which has received FDA RMAT designation and shown early signals of deep B‑cell depletion and clinical activity with a fludarabine‑free or conditioning‑free approach. Additional programs include FT825 for HER2-positive solid tumors, FT836 and FT839 next‑generation CAR T cells incorporating Sword & Shield and dual‑CAR designs, and FT522, a CAR NK cell using Alloimmune Defense Receptor technology to reduce reliance on intensive chemotherapy.
The report highlights a broad risk profile typical for early-stage biotechnology, including heavy funding needs, clinical and regulatory uncertainty, complex manufacturing, reliance on partners such as Ono Pharmaceutical, and extensive dependence on patents and licensed technologies to protect its iPSC platform and product candidates.
Fate Therapeutics, Inc. reported fourth-quarter and full-year 2025 results and highlighted progress in its off-the-shelf CAR T-cell pipeline. For 2025, collaboration revenue was $6.6 million, down from $13.6 million in 2024, reflecting lower partnered activity. Total operating expenses fell sharply to $154.4 million from $223.9 million, driven by lower research and development and general and administrative costs, including reduced stock-based compensation and the absence of prior-year impairment.
The company’s 2025 net loss narrowed to $136.3 million from $186.3 million, with basic and diluted net loss per share improving to $1.15 from $1.64. As of December 31, 2025, Fate held $205.1 million in cash, cash equivalents, and investments, and common shares outstanding were 115.4 million. Management projects an operating runway through year-end 2027, supported by this cash position and an expected 30% reduction in 2025 operating expenses versus 2024, which they believe will enable key clinical and collaboration milestones.
Operationally, the company advanced FT819, its off-the-shelf CD19 CAR T-cell program for autoimmune diseases, including outpatient treatment and enrollment across 16 sites, and reported early clinical activity for FT836 in colorectal cancer without conditioning chemotherapy, alongside preclinical progress for FT839.
Fate Therapeutics reported new equity awards to Chief Legal and Compliance Officer Cindy Tahl. On January 15, 2026, she was granted 100,000 shares of common stock at an acquisition price of $0.00, reported as an award of restricted stock units. These RSUs vest in four equal installments on January 8, 2027, 2028, 2029 and 2030, with each RSU converting into one share of common stock upon settlement. Following this grant, she beneficially owns 487,081 common shares directly.
She was also granted a stock option for 400,000 shares of common stock with an exercise price of $1.05 per share. This option vests in 36 equal monthly installments after January 1, 2026, becoming fully vested and exercisable on January 1, 2029, contingent on continued service with the company.